# US 2010/0303812 A1 · Neutralizing monoclonal antibody against human dll4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303812 A1
- Document ID: US20100303812A1
- Status: Published application
- Kind: A1
- Application number: 12/599,804
- Filed: 2008-05-15
- Published: 2010-12-02
- Earliest claimed: 2007-05-15
- Assignees: Smart Targeting Limited
- Inventors: Makoto Sunamura; Hideo Yagita
- Web page: https://patentgrep.com/patent/US20100303812A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/18: Feminine contraceptives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a binding protein capable of binding to DLL4 as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.

## Claims

### Claim 1

A binding protein capable of binding to human DLL4, which binding protein comprises at least one CDR domain selected from
(a) a light chain CDR 1 comprising the amino acid sequence RASSSVSFMH (SEQ ID NO; 6), or a sequence substantially homologous thereto;
(b) a light chain CDR 2 comprising the amino acid sequence ATSNLTS (SEQ ID NO: 7), or a sequence substantially homologous thereto;
(c) a light chain CDR3 comprising the amino acid sequence QQWSSNPFT (SEQ ID NO: 8), or a sequence substantially homologous thereto;
(d) a heavy chain CDR1 comprising the amino acid sequence SYVMH (SEQ ID NO. 3), or a sequence substantially homologous thereto;
(e) a heavy chain CDR2 comprising the amino acid sequence YIIPYNDGTKYNEKFKG (SEQ ID NO. 4), or a sequence substantially homologous thereto; and
(f) a heavy chain CDR3 comprising the amino acid sequence SEDYDHFDY (SEQ ID NO: 5), or a sequence substantially homologous thereto.

### Claim 2 (depends on 1)

A binding protein according to claim 1, wherein said binding protein comprises at least 2 CDR domains selected from (a)-(f) as defined in claim 1.

### Claim 3 (depends on 1)

A binding protein according to claim 1, wherein said binding protein comprises at least 1 light chain CDR domain selected from (a)-(c) as defined in claim 1 and at least 1 heavy chain CDR domain selected from (d)-(f) as in claim 1.

### Claim 4 (depends on 1)

A binding protein according to claim 1, wherein said binding protein comprises 3 light chain CDR domains as defined in (a) to (c) in claim 1 and/or 3 heavy chain CDR domains as defined in (d) to (f) in claim 1.

### Claim 5 (depends on 1)

A binding protein according to claim 1, wherein said binding protein comprises a VH domain which has the amino acid sequence of SEQ ID NO: 1, or a sequence substantially homologous thereto, and/or a VL domain which has the amino acid sequence of SEQ ID NO: 2, or a sequence substantially homologous thereto.

### Claim 6 (depends on 1)

A binding protein according to claim 1, wherein said binding protein comprises one or more of the framework regions disclosed in SEQ ID Nos 9, 10, 11, 12, 13, 14, 15 or 16, or framework regions substantially homologous thereto.

### Claim 7 (depends on 1)

A binding protein according to claim 1, wherein said binding protein is an antibody or antibody fragment.

### Claim 8 (depends on 1)

A binding protein according to claim 1, wherein said binding protein is chimeric or humanised.

### Claim 9 (depends on 1)

A binding protein according to claim 1, wherein said binding protein is a chimeric antibody comprising a human CH1 heavy chain constant domain and a human kappa light chain constant domain.

### Claim 10 (depends on 1)

A binding protein according to claim 1, wherein said binding protein has a KD of less than 10×10−10 or 5×10−10.

### Claim 11 (depends on 1)

A binding protein according to claim 1, wherein said binding protein can inhibit or significantly reduce the function of DLL4 or prevent DLL4 interacting with one or more of its natural ligands and/or receptors.

### Claim 12 (depends on 1)

A nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1.

### Claim 13 (depends on 1)

A nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1, wherein said nucleic acid molecule comprises a nucleic acid molecule as defined in SEQ ID NO: 17 or SEQ ID NO: 18, or nucleic acid sequences complimentary thereto or nucleic acid molecules substantially homologous thereto.

### Claim 14 (depends on 1)

A recombinant expression vector comprising one or more nucleic acid molecules comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 and a regulatory sequence for the transcription and translation of the protein sequence encoded by said nucleic acid molecule.

### Claim 15 (depends on 1)

A host cell comprising a nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 or a recombinant expression vector comprising one or more nucleic acid molecules comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 and a regulatory sequence for the transcription and translation of the protein sequence encoded by said nucleic acid molecule.

### Claim 16 (depends on 1, 15)

A method of producing a binding protein according to claim 1 comprising a step of culturing a host cell according to claim 15.

### Claim 17 (depends on 1)

A fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence.

### Claim 18 (depends on 1)

A conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent.

### Claim 19 (depends on 1)

A fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence or a conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent, wherein said fusion protein or conjugate comprises a cytotoxic polypeptide, radionucleotide, cytokine, antibody molecule, immunoglobulin, hormone, growth factor, lectin, insulin, low density lipoprotein, glucagon, endorphin, transferrin, bombesin, asialoglycoprotein glutathione-S-transferase (GST), hemagglutinin (HA), truncated myc, enzyme or component of the T-cell receptor signalling system.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method of treatment of a disorder or condition characterised by aberrant DLL4 signalling and/or aberrant angiogenesis wherein an effective amount of a binding protein according, to claim 1, fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence, conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent, nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 or vector comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 is administered to a subject or to a sample removed from a subject and which is subsequently returned to the subject.

### Claim 23 (depends on 1)

A method of diagnosis of a disorder or condition characterised by aberrant DLL4 signalling and/or aberrant angiogenesis or imaging wherein an effective amount of a binding protein according to claim 1, fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence, conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent, nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 or vector comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 is administered to a subject or to a sample removed from a subject and which is subsequently returned to the subject and the presence and/or amount and/or the location of the binding protein or binding protein conjugate in the subject is detected.

### Claim 24 (depends on 22)

A method according to claim 22, wherein said disorder or condition is selected from atherosclerosis, arthritis, ocular neovascularisation, endometriosis, uterine fibroids, pre-eclampsia and cancer.

### Claim 25 (depends on 24)

A method according to claim 24, wherein said disorder or condition is selected from prostate cancer and pancreatic cancer.

### Claim 26 (depends on 1)

A method of contraception wherein an effective amount of a binding protein according to claim 1, fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence, conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent, nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 or vector comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 is administered to a subject or to a sample removed from a subject and which is subsequently returned to the subject.

### Claim 27 (depends on 1)

An in vitro method for modulating the level and/or function of DLL4, wherein a binding protein according to claim 1, fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence, conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent, nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 or vector comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 is administered to a tissue sample, cell culture or cell.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 1)

A method of improving the outcome of transplantation therapy, which method comprises administration of an effective amount a binding protein according to claim 1, fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence, conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent, nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 or vector comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 to a patient or a transplant before, during and/or after transplantation has been carried out.

### Claim 31 (depends on 1)

A composition comprising a binding protein according to claim 1, fusion protein comprising a binding protein according to claim 1 and a further polypeptide sequence, conjugate of a binding protein according to claim 1 and a biologically active molecule or medically relevant agent, nucleic acid molecule comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1 or vector comprising a sequence encoding or complimentary to a sequence encoding a binding protein according to claim 1, and a pharmaceutically acceptable excipient, carrier, diluent, buffer or stabilizer.

### Claim 32 (depends on 1)

A method of producing a binding protein capable of binding to human DLL4, comprising the addition, deletion, substitution and/or insertion of one or more amino acids into the amino acid sequence of a parent binding protein to form a new binding protein, and testing the resulting new binding protein for binding to human DLL4, wherein said parent binding protein is a binding protein according to claim 1.

### Claim 33 (depends on 23)

A method according to claim 23, wherein said disorder or condition is selected from atherosclerosis, arthritis, ocular neovascularisation, endometriosis, uterine fibroids, pre-eclampsia and cancer.

### Claim 34 (depends on 34)

A method according to claim 34, wherein said disorder or condition is selected from prostate cancer and pancreatic cancer.
